North American Management’s Teva Pharmaceuticals TEVA Stock Holding History

North American Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,500	Closed	-$253K	–	136
2016 Q3	$253K	Hold	5,500	–	–	0.04%	121
2016 Q2	$276K	Buy	+5,500	New	+$293K	0.05%	118

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

North American Management's TEVA Position: Q4 2016 in Review

North American Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 5,500 shares — an estimated $253K sold.

North American Management first reported a position in TEVA in Q2 2016 and held it in 2 quarters. The position peaked at $276K in Q2 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

North American Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
North American Management sold 5,500 Teva Pharmaceuticals shares in Q4 2016, an estimated $253K.
North American Management first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 2 quarters.
North American Management's Teva Pharmaceuticals position peaked at $276K in Q2 2016.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on North American Management's 13F filing for Q4 2016, filed 26 Jan 2017.